Scholarlink

Background <p>Despite advances in lipid-lowering, antithrombotic, and interventional therapies, coronary heart disease (CHD) remains associated with a&#xa0;substantial risk of recurrent cardiovascular events. Inflammation has emerged as a&#xa0;major contributor to this residual risk. Experimental and clinical evidence indicates that inflammatory pathways, particularly activation of the NOD-like receptor family pyrin domain containing&#xa0;3 (NLRP3) inflammasome and, downstream, the interleukin-1β–interleukin-6–C-reactive protein (CRP) axis, play a&#xa0;key role in atherosclerotic plaque progression and destabilization.</p> Objectives <p>This review summarizes the clinical evidence for anti-inflammatory therapies in patients with CHD.</p> Current data <p>The CANTOS trial provided the first evidence that inhibition of interleukin-1β in CHD patients with elevated CRP reduces major adverse cardiovascular events independently of lipid lowering. Low-dose colchicine significantly reduced cardiovascular events in several trials, both early after myocardial infarction and in patients with chronic coronary disease.</p> Conclusions <p>These findings establish inflammation as a&#xa0;modifiable therapeutic target in the secondary prevention of CHD and support colchicine as the most advisable anti-inflammatory treatment currently available for CHD.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Antiinflammatorische Therapiestrategien bei koronarer Herzkrankheit

  • 期刊论文

  • 发表日期：

    2026年3月11日

查看全文
  • Ulrich Hofmann

摘要

Background

Despite advances in lipid-lowering, antithrombotic, and interventional therapies, coronary heart disease (CHD) remains associated with a substantial risk of recurrent cardiovascular events. Inflammation has emerged as a major contributor to this residual risk. Experimental and clinical evidence indicates that inflammatory pathways, particularly activation of the NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome and, downstream, the interleukin-1β–interleukin-6–C-reactive protein (CRP) axis, play a key role in atherosclerotic plaque progression and destabilization.

Objectives

This review summarizes the clinical evidence for anti-inflammatory therapies in patients with CHD.

Current data

The CANTOS trial provided the first evidence that inhibition of interleukin-1β in CHD patients with elevated CRP reduces major adverse cardiovascular events independently of lipid lowering. Low-dose colchicine significantly reduced cardiovascular events in several trials, both early after myocardial infarction and in patients with chronic coronary disease.

Conclusions

These findings establish inflammation as a modifiable therapeutic target in the secondary prevention of CHD and support colchicine as the most advisable anti-inflammatory treatment currently available for CHD.